Correlation between platelet-derived microparticles and soluble L-selectin in patients undergoing hemodialysis

• References

• 1 Windus DW. Permanent vascular access: a nephrologist's view. Am J Kidney Dis 1993; 21: 457-71.
• 2 Hakim R, Himmelfarb J. Hemodialysis access failure: a call to action. Kidney 1998; 54: 1029-40.
• 3 Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 1994; 72: 151-4.
• 4 Blann AD, Morris J, McCollum C. Soluble L-selectin in peripheral arterial disease: relationship with soluble E-selectin and soluble P-selectin. Atherosclerosis 1996; 126: 227-31.
• 5 Castillo R, Lozano T, Escolar G. et al. Defective platelet adhesion on vessel subendothelium in uremic patients. Blood 1986; 68: 337-42.
• 6 Escolar G, Cases A, Bastida E. et al. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein Ilb-IIIa. Blood 1990; 76: 1336-40.
• 7 Sloand EM, Sloand JA, Prodouz K. et al. Reduction of platelet glycoprotein lb in uraemia. Br J Haematol 1991; 77: 375-81.
• 8 Gawaz MP, Dobos G, Spath M. et al. Impaired function of platelet membrane glycoprotein Ob-Ola in end-stage renal disease. J Am Soc Nephrol 1994; 05: 36-46.
• 9 Bloembergen WE, Port FK, Mauger EA. et al. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995; 06: 177-83.
• 10 London GM, Drake TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51: 1678-95.
• 11 Nomura S. Function and clinical significance of platelet-derived microparticles. Int J Hematol 2001; 74: 397-404.
• 12 Sims PJ, Faioni EM, Wiedmer T. et al. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205-12.
• 13 Nomura S, Komiyama Y, Miyake T. et al. Amyloid p-protein precursor-rich platelet micro-particles in thrombotic disease. Thromb Haemost 1994; 72: 519-22.
• 14 Nomura S, Suzuki M, Katsura K. et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 1995; 116: 235-40.
• 15 Osumi K, Ozeki Y, Saito S. et al. Development and assessment of enzyme immunoassay for platelet-derived microparticles. Thromb Haemost 2001; 85: 326-30.
• 16 Chuang YC, Chen JB, Yang LC. et al. Significance of platelet activation in vascular access survival of haemodialysis patients. Nephrol Dial Transplant 2003; 18: 947-54.
• 17 Ando M, Iwata A, Ozeki Y. et al. Circulating platelet-derived microparticles with procoagu-lant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 2002; 62: 1757-63.
• 18 Barry OP, Pratico D, Savani RC. et al. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 1998; 102: 136-44.
• 19 Nomura S, Tandon NN, Nakamura T. et al. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277-87.
• 20 Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
• 21 Kushiya F, Wada H, Sakura M. et al. Atherosclerotic and hemostatic abnormalities in patients undergoing hemodialysis. Clin Appl Thromb/Hemost 2003; 09: 53-60.